Cellebrite Di Ltd. · NASDAQ:CLBT
Cellebrite Di — Q1 2025 Earnings Presentation
21 slides from Cellebrite Di's earnings presentation, May 14, 2025
Slide 1: Cellebrite Investor Call
ivCellebrite =. a a Cellebrite Investor Call Nasdaq: Investor Relations 05.14.2025
Slide 2: Disclaimer
This presentation has been prepared by Cellebrite DI Ltd. (the “Company”) solely for informational purposes. It is not, and should not be assumed to be, complete. This presentation is not an offer to sell DISCLAIMER securities, nor is it a solicitation of an offer to buy securities. This presentatio
Slide 3: Agenda
AGENDA → Q1 2025 Results Highlights → 2025 Strategic Progress → Market Conditions & Outlook → Financial Review → Q&A
Slide 4: Results Highlights
4 RESULTS HIGHLIGHTS Rule of X $90M $108M +20% 47 48 Q1 24 Total Revenue – Q1 25 $79M $96M +21% 20% 25% Q1 24 Subscription Revenue – Q1 25 $332M $408M +23% MAR 24 ARR – MAR 25 27% 23% $18M 20% $24M 22% Q1 24 Adj. EBITDA & Adj. EBITDA %* – Q1 25 TTM 3/24 TTM 3/25 ARR Growth Adj. EBITDA Margin * Non-G
Slide 5: Strategic Progress & Recent Developments
5 STRATEGIC PROGRESS & RECENT DEVELOPMENTS Events Innovation CEO Search Update
Slide 6: Summary
6 Summary The world needs the mission- We are committed to Our mission and our impact The future remains incredibly critical IP we uniquely deliver extending our capabilities in remain in the early innings bright for this Company AI, cloud-related agility, and investigative case and evidence managem
Slide 7: Financial Review
FINANCIAL REVIEW | | | a | | i f e 2025 cellebrite a1 2025 investor call | = —> — — | 05.14.2025
Slide 8: ARR Growth
8 ARR GROWTH ($ in millions) $408.1 $331.8 → Mar-25 ARR grew 23% → Gross revenue retention ~92% → Existing customer expansion fuels most of the ARR growth Mar-24 Mar-25 Pathfinder & Guardian Families Inseyets Family Mar-24
Slide 9: Q1 25 Wins
9 ARR EXPANSION | Q125 WINS $104M Federal Public • Goal: Accelerate responsiveness to collect digital evidence (Net New ARR) • Deploying Inseyets offline to equip forensics vehicles and Safety Agency support evidence collection at crime scenes (field use case) (Latin America) Pathfinder & • New logo
Slide 10: Revenue Growth Driven by Subscription
10 REVENUE GROWTH DRIVEN BY SUBSCRIPTION (in millions) 20% 8% 7% 9% 7% 7% 4% 4% 7.3 4% 4% 6% 4.4 Total revenue 6.8 growth 3.6 88% 89% 87% 87% 89% 21% 95.8 Total subscription 79.2 revenue growth Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q1 24 Q1 25 Note: Numbers may not total 100% due to rounding. Note: Numbers
Slide 11: Gross Margin and Operating Costs
11 GROSS MARGIN AND OPERATING COSTS Cost of Goods Sold (Non-GAAP, $M) and Operating Expense (Non-GAAP, $M) and Gross Margin (Non-GAAP, %) Operating Expense Margin (Non-GAAP, %) 84% 84% 64% 84% 60% 86% 68% 63% 58% 86% $17.0 $16.7 $68.8 $15.6 $14.9 $60.9 $60.3 $62.5 $65.1 $12.8 Q1 24 Q2 24 Q3 24 Q4 24
Slide 12: Adjusted EBITDA & Cash Position
12 ADJUSTED EBITDA & CASH POSITION Adjusted EBITDA (Non-GAAP, $M) and Cash Position Adjusted EBITDA Margin (Non-GAAP, %) $509.8M (3/31/25) +$26.0M from Q4 24 | +$162.5 from Q1 24 29% Cash and 26% $31.3 cash $28.8 equivalents 22% 23% Deposits 18% $23.7 35% 20% $21.6 $17.6 Short-term and long-term mar
Slide 13: Financial Forecast
13 FINANCIAL FORECAST Q2 ‘25 FY ‘25 2024A EXPECTATIONS EXPECTATIONS (AS OF 05/14/25) (AS OF 05/14/25) ARR $396M $416M - $426M $480 - $495M ARR Growth (y/y) +25% +20% - +23% +21% - +25% Revenue $401M $110M - $116M $470M - $485M Revenue Growth (y/y) +23% +15% - +21% +17% - +21% Adjusted EBITDA* $99.4M
Slide 14: ms i
ms 1 i 05.14.2025 @.; a | sl ae Aer ae un © 2026 Cellebrite @1 2025 Investox Call | = —> — — |
Slide 15: Appendix
N N ™~! . \ a mane “~.% 1 Se h i © 2025 Cellebrite @1 2025 Investor Call 05.14.2025
Slide 16: Appendix Financial Summary
APPENDIX FINANCIAL SUMMARY → Q125 & Q124 For the three months ended March 31, (U.S Dollars in thousands) 2025 2024 Revenue 107,549 89,582 Gross profit 90,059 76,318 Gross margin 83.7% 85.2% Operating income 12,268 9,247 Operating margin 11.4% 10.3% Net income (loss) 17,400 (71,372) Cash flow from op
Slide 17: Appendix Cost of Revenue and Gross Profit
APPENDIX COST OF REVENUE AND GROSS PROFIT → RECONCILIATION For the three months ended Q125 & Q124 March 31, 2025 2024 (Unaudited) (Unaudited) (U.S Dollars in thousands) Cost of revenue $ 17,490 $ 13,264 Less: Share-based compensation 750 430 Acquisition-related costs — 2 Non-GAAP cost of revenue $ 1
Slide 18: Appendix Operating Expense & Operating Income
APPENDIX OPERATING EXPENSE & OPERATING INCOME → RECONCILIATION For the three months ended March 31, Q125 & Q124 2025 2024 (Unaudited) (Unaudited) Operating expenses $ 77,791 $ 67,071 (U.S Dollars in thousands) Less: Share-based compensation 8,027 5,266 Amortization of intangible assets 926 927 Acqui
Slide 19: Appendix Net Income & EPS
APPENDIX NET INCOME & EPS → RECONCILIATION For the three months ended March 31, Q125 & Q124 2025 2024 (Unaudited) (Unaudited) Net income (loss) $ 17,400 $ (71,372) (U.S Dollars in thousands) Share-based compensation 8,777 5,696 Amortization of intangible assets 926 927 Acquisition-related costs — 9
Slide 20: Appendix Adjusted EBITDA
APPENDIX ADJUSTED EBITDA → RECONCILIATION For the three months ended March 31, Q125 & Q124 2025 2024 (Unaudited) (Unaudited) Net income (loss) $ 17,400 $ (71,372) (U.S Dollars in thousands) Financial (income) expense, net (7,060) 78,576 Tax expense 1,928 2,043 Share-based compensation 8,777 5,696 Am
Slide 21: Appendix Definitions
APPENDIX DEFINITIONS → Annual Recurring Annual recurring revenue (ARR) is defined as the annualized value of active Revenue term-based subscription license contracts and maintenance contracts related to perpetual licenses in effect at the end of that period. Subscription license contracts and mainte